Biogen Q1 Earnings Miss Estimates; Outlook In -Line
Leading biotech Biogen Idec (BIIB) traded down 3% early Tuesday after its first-quarter results missed Wall Street's expectations. The company said sales rose 7% over the year-ago quarter to $1.3 billion, essentially the same as analysts expected, but profit of $1.40 a share was down from last year and 8 cents below estimates. Like its fellow biotech Celgene (CELG) last week, Biogen blamed problems in the month of January specifically, which
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here